Author: Ken Dropiewski

Northwestern Memorial Hospital Surgeon First in Illinois to Repair Aortic Valve with Novel Ring

CHICAGO, March 29, 2018 /PRNewswire/ — A Northwestern Memorial Hospital cardiac surgeon helped pioneer the use of an U.S. Food and Drug Administration (FDA) approved aortic valve ring as part of a triple valve repair, the first of its kind in the United States. S. Chris Malaisrie, MD, has performed two successful surgeries using the […]

Marketwired: Mar 29, 2018 — Novoheart Files Patent Application on Disease Modeling Based on Landmark Research Conducted During Second Contract with Global Pharma Partner

VANCOUVER, BRITISH COLUMBIA — (Marketwired) — Mar 29, 2018 — Novoheart (“Novoheart” or the “Company”) (TSX VENTURE: NVH)(FRANKFURT: 3NH) is pleased to announce that it has filed a patent application on the use of its proprietary MyHeart™ Platform of human bioengineered heart tissues to create disease models for neurological diseases in which […]

Corvidia Therapeutics Appoints Marc de Garidel as Chief Executive Officer

WALTHAM, Mass.–(BUSINESS WIRE)– Corvidia Therapeutics Inc., a leading clinical stage biotechnology company, today announced the appointment of Marc de Garidel as Chief Executive Officer. Mr. de Garidel succeeds Corvidia’s Michael Davidson, M.D., who will remain on the company’s executive team as Chief Scientific Officer. “As we transition from a clinical stage […]

MIVI Neuroscience Begins European Commercialization After Achieving CE Mark Approval Of The R4Q Revascularization Catheter For Ischemic Stroke

EDEN PRAIRIE, Minn., March 29, 2018 /PRNewswire/ — MIVI Neuroscience, Inc. announced today it has received CE Mark approval for the R4Q Revascularization Catheter for the removal of fresh, soft emboli and thrombi in the peripheral and neurovascular systems. The CE Mark approval is a significant accomplishment for MIVI Neuroscience.  This approval enables the […]

EP Solutions’ Scientific and Mathematics Advisory Boards Endorse Company Strategy

YVERDON-LES-BAINS, Switzerland, March 29, 2018 /PRNewswire/ — Dr. Joaquin Azpilicueta, M.D., EP Solutions CEO reports the outcome of the meetings with the Scientific Advisory Board and the Mathematics Advisory Board celebrated in February and March 2018 respectively. The Scientific Advisory Board, with members that hold prominent positions in the cardiac electrophysiology community like Prof. Dr. Claudio Tondo, […]

Inari Medical Announces Completion of $27 Million Series C Financing

IRVINE, Calif., March 29, 2018 /PRNewswire/ — Inari Medical, Inc., announced today the close of a Series C financing totaling $27.0 million.  The financing was led by new investor Gilde Healthcare and was joined by all of Inari’s existing investors including Versant Ventures and U.S. Venture Partners.  Geoff Pardo of Gilde Healthcare will join Inari’s Board […]

IDx Founder Awarded Patent for System that Automatically Detects Measure of Cardiovascular Health

IOWA CITY, Iowa, March 29, 2018 /PRNewswire/ — IDx, a privately-held AI diagnostics company, today announced its founder and president, Michael Abramoff, MD, PhD, has been awarded U.S. Patent No. 9,924,867 for a system that can automatically measure arterial and venous diameters in blood vessels, an important predictor of cardiovascular health.  “It is exciting that […]

LivaNova Bicarbon Aortic Valves Receive CE Mark for Expanded Use Labeling with Lower-Dose Blood Thinners in Low-Risk Patients

LONDON–(BUSINESS WIRE)–LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, has received CE Mark approval for its Bicarbon® aortic valves for use with low-dose anticoagulant therapy. The expanded CE labeling means that a lower international normalized ratio (INR), the standardized index used to measure blood coagulability, can be […]

Abbott Initiates Trial to Evaluate Improved Survival And Outcomes with the CardioMEMS Monitor

ABBOTT PARK, Ill., March 29, 2018 /PRNewswire/ — Abbott (NYSE: ABT) announced today the company has initiated the landmark GUIDE-HF clinical trial using the CardioMEMS™ HF System. The GUIDE-HF trial will study whether the CardioMEMS device can improve survival and quality of life for people living with New York Heart Association (NYHA) Class II – IV heart failure. The […]